If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

Acquisition & Research Agreement

13 Sep 2010 07:00

RNS Number : 5363S
Immunodiagnostic Systems Hldgs PLC
13 September 2010
 



Immunodiagnostic Systems Holdings plc

 

Acquisition and Research Agreement

 

Immunodiagnostic Systems Holdings plc ("IDS"), a leading producer of diagnostic testing kits for the clinical and research markets, announces that it has acquired 100% of the share capital of MGP Diagnostics AS of Mjøndalen, Norway (MGPD) for an undisclosed cash consideration.

 

MGPD is a non-trading company owning a portfolio of patents relating to the determination of a unique biomarker called Matrix GLA protein (mGLA). There is growing evidence that mGLA is a controlling factor in the inappropriate calcification of soft tissues such as the carotid arteries and heart valves, with an increasing number of publications appearing in the scientific literature in recent years.

 

Vascular calcification is known to play a significant role in the development of cardiovascular disease (CVD). It is particularly common in patients suffering from chronic kidney disease (CKD) and those on kidney dialysis, who commonly develop bone disease as a result of their failing kidneys. More than 80% of dialysis patients develop some degree of coronary artery calcification.

 

IDS also announces that it has entered into a Research Agreement with VitaK BV of Maastricht in the Netherlands. VitaK is the leading research establishment in mGLA biology in the world, having filed the original patents now acquired by IDS from MGPD. IDS and VitaK will work closely to accelerate the proof of concept studies needed to establish the clinical utility of mGLA.

 

Dr Roger Duggan, CEO of IDS, commented: "This acquisition provides IDS with an IP-protected entry into an adjacent, highly complementary area of potential clinical importance. Calcification of bones and teeth is highly desirable, but in soft tissues such as arteries and heart valves is potentially lethal. The future availability of a serum biomarker for early diagnosis and the monitoring of therapy will provide a valuable tool to cardiovascular and renal physicians throughout the world."

 

For further information:

 

Immunodiagnostic Systems Holdings PLC

Tel: 0191 519 0660

Roger Duggan, CEO

Ian Cookson, COO

Paul Hailes, Finance Director

Walbrook PR Ltd

Tel: 020 7933 8787

Paul McManus

Mob: 07980 541 893

paul.mcmanus@walbrookpr.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAKKBDBDBKDNCD
Date   Source Headline
6th Dec 20182:59 pmRNSDirector/PDMR Shareholding
23rd Nov 20185:04 pmRNSHalf-year Report
19th Oct 20185:18 pmRNSH1 Trading Update
4th Sep 20188:00 amRNSCompletion of Share Buyback
30th Aug 20187:00 amRNSProposed Share Buyback
7th Aug 20185:48 pmRNSTransaction in Own Shares
7th Aug 20187:00 amRNSTransaction in Own Shares
1st Aug 20186:06 pmRNSTransaction in Own Shares
31st Jul 20186:02 pmRNSTransaction in Own Shares
26th Jul 20185:59 pmRNSResult of AGM
26th Jul 20187:00 amRNSAGM Statement
11th Jul 20185:33 pmRNSTransaction in Own Shares
20th Jun 20187:05 amRNSPublication of Annual Report and Accounts
20th Jun 20187:00 amRNSFinal Results
13th Jun 20185:07 pmRNSTransaction in Own Shares
6th Jun 20188:04 amRNSTransaction in Own Shares
20th Apr 20184:35 pmRNSTrading Statement
12th Apr 20185:21 pmRNSTransaction in Own Shares
6th Apr 20185:47 pmRNSTransaction in Own Shares
5th Apr 20182:16 pmRNSTransaction in Own Shares
29th Mar 20186:25 pmRNSDirector/PDMR Shareholding
29th Mar 20186:21 pmRNSDirector/PDMR Shareholding
29th Mar 20181:32 pmRNSLaunch of two new automated assays
29th Mar 20187:00 amRNSTransaction in Own Shares
26th Mar 20185:08 pmRNSTransaction in Own Shares
23rd Mar 20183:59 pmRNSTransaction in Own Shares
21st Mar 20185:50 pmRNSDirectorate Change
21st Mar 20181:08 pmRNSDirector/PDMR Shareholding
1st Mar 20184:50 pmRNSTransaction in Own Shares
22nd Feb 20185:02 pmRNSTransaction in Own Shares
21st Feb 20185:30 pmRNSTransaction in Own Shares
15th Feb 20185:20 pmRNSTransaction in Own Shares
13th Feb 201812:13 pmRNSTransaction in Own Shares
12th Feb 20181:22 pmRNSTransaction in Own Shares
6th Feb 20184:49 pmRNSTransaction in Own Shares
5th Feb 20183:19 pmRNSTransaction in Own Shares
2nd Feb 20182:47 pmRNSTransaction in Own Shares
24th Jan 20181:21 pmRNSTransaction in Own Shares
16th Jan 20187:00 amRNSPartnership Agreement with Technogenetics
15th Jan 20184:45 pmRNSTransaction in Own Shares
27th Dec 20175:16 pmRNSTransaction in Own Shares
24th Nov 20174:30 pmRNSHalf-year Report
23rd Nov 20175:15 pmRNSTransaction in Own Shares
14th Nov 201712:06 pmRNSTransaction in Own Shares
13th Nov 20175:37 pmRNSTransaction in Own Shares
2nd Nov 20176:05 pmRNSTransaction in Own Shares
1st Nov 20174:29 pmRNSAdditional Listing
1st Nov 20174:05 pmRNSTransaction in Own Shares
31st Oct 20176:22 pmRNSDirectorate Change
31st Oct 20176:03 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.